gabexate has been researched along with Heart Disease, Ischemic in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response characteristics of these three protease inhibitors were bell shaped, and the optimal concentrations of nafamostat mesilate, gabexate mesilate, and NCO-700 were 5 microM, 100 microM, and 20 microM, respectively." | 1.30 | Effects of protease inhibitors on postischemic recovery of the heart. ( Kinoshita, H; Shibata, T; Suehiro, S; Yamamoto, F, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shibata, T | 1 |
| Yamamoto, F | 1 |
| Suehiro, S | 1 |
| Kinoshita, H | 1 |
1 other study available for gabexate and Heart Disease, Ischemic
| Article | Year |
|---|---|
Effects of protease inhibitors on postischemic recovery of the heart.
Topics: Animals; Benzamidines; Creatine Kinase; Gabexate; Glycoproteins; Guanidines; Heart; In Vitro Techniq | 1997 |